Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Director | February 20, 2026 | February 24, 2026 |
| T2 Biosystems, Inc.TTOO · Entity 11728 | Director | June 11, 2019 | June 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 337,392 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 123,000 · Balance 337,392 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed
T2 Biosystems, Inc.
Report date June 11, 2019 · Filed June 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,010 |
Reported balance
After 2019-06-11 transaction · row 1
1 source rowRow 1 · 2019-06-11 · Sale · Disposed 9,000 · Balance 53,010 F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2019, to cover payment of tax liability incident to the vesting of restricted stock units. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.38 to $1.46. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2019, to cover payment of tax liability incident to the vesting of restricted stock units.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.38 to $1.46. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 24, 2026 23:44 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000070 · form4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,392 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:28 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 112,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003193 · form4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,392 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:48 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001062993-24-004285 · form4.xml · derivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 00:53 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 9,747 | $1.45 | $14,133.15 |
DisclosureSEC source: 0001062993-23-018552 · form4.xml · nonDerivative · entry 4 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,592 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 00:53 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 10,000 | $1.43 | $14,300.00 |
DisclosureSEC source: 0001062993-23-018552 · form4.xml · nonDerivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,339 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 26, 2023 Filed Sep 28, 2023 00:53 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 10,000 | $1.47 | $14,740.00 |
DisclosureSEC source: 0001062993-23-018552 · form4.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,339 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 25, 2023 Filed Sep 28, 2023 00:53 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 200 | $1.43 | $286.00 |
DisclosureSEC source: 0001062993-23-018552 · form4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,339 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 22:39 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 100 | $1.44 | $144.00 |
DisclosureSEC source: 0001062993-23-018421 · form4.xml · nonDerivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,539 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. Read SEC document |
| September 21, 2023 Filed Sep 28, 2023 00:50 UTC Amendment | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 100 | $1.44 | $144.00 |
DisclosureSEC source: 0001062993-23-018551 · form4a.xml · nonDerivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,539 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 22:39 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 412 | $1.44 | $593.28 |
DisclosureSEC source: 0001062993-23-018421 · form4.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,639 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 22:39 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 3,405 | $1.45 | $4,937.25 |
DisclosureSEC source: 0001062993-23-018421 · form4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,051 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. Read SEC document |
| September 20, 2023 Filed Sep 28, 2023 00:50 UTC Amendment | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 412 | $1.44 | $593.28 |
DisclosureSEC source: 0001062993-23-018551 · form4a.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,639 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| September 20, 2023 Filed Sep 28, 2023 00:50 UTC Amendment | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 3,405 | $1.45 | $4,937.25 |
DisclosureSEC source: 0001062993-23-018551 · form4a.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,051 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. F3 · ownership.direct: The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:39 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001062993-23-002038 · form4.xml · derivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common stock · 175,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 15:46 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 16,864 | $1.70 | $28,668.80 |
DisclosureSEC source: 0001062993-22-019850 · form4.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,456 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which will vest September 20, 2023. Under the plan, unvested shares are subject to forfeiture if the requisite service period is not completed. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 15:46 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | SaleCommon stock | 17,000 | $1.71 | $29,013.90 |
DisclosureSEC source: 0001062993-22-019850 · form4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,320 F1 · kind: Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock. F2 · balance_after: Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which will vest September 20, 2023. Under the plan, unvested shares are subject to forfeiture if the requisite service period is not completed. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:23 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 59,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001062993-22-005490 · form4.xml · derivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common stock · 59,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting March 31, 2022. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:30 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | SaleCommon Stock | 9,000 | $1.44 | $12,960.00 |
DisclosureSEC source: 0000899243-19-016822 · doc4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,010 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2019, to cover payment of tax liability incident to the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.38 to $1.46. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2019 Filed Jun 11, 2019 18:23 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-016463 · doc4.xml · derivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On June 8, 2018 the reporting person was granted 9,000 restricted stock units that vested on June 8, 2019. F2 · derivative.expiration_date: On June 8, 2018 the reporting person was granted 9,000 restricted stock units that vested on June 8, 2019. Read SEC document |
| June 08, 2019 Filed Jun 11, 2019 18:23 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-016463 · doc4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 18:23 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000899243-19-016463 · doc4.xml · derivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-07 F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 substantially equal monthly installments commencing June 7, 2019. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 14:05 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,058 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0000899243-18-028518 · doc4.xml · derivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,058 shares Expires 2019-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 14:05 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | SaleCommon Stock | 6,048 | $5.29 | $31,993.92 |
DisclosureSEC source: 0000899243-18-028518 · doc4.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,010 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.27 to $5.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 14:05 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 27,058 | $1.16 | $31,387.28 |
DisclosureSEC source: 0000899243-18-028518 · doc4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 11:40 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016142 · doc4.xml · derivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 8, 2019. F2 · derivative.expiration_date: The restricted stock units vest on June 8, 2019. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 16:42 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | SaleCommon Stock | 6,000 | $8.87 | $53,220.00 |
DisclosureSEC source: 0000899243-18-015110 · doc4.xml · nonDerivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F2 · kind: Represents shares sold to cover payment of tax liability incident to the vesting of RSUs originally granted to the reporting person on June 2, 2017. Read SEC document |
| June 02, 2018 Filed Jun 5, 2018 16:42 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015110 · doc4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:15 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001104659-17-038155 · a4.xml · derivative · entry 2 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,058 Underlying: Common Stock · 20,000 shares Expires 2019-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:15 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionCommon Stock | 20,000 | $1.16 | $23,200.00 |
DisclosureSEC source: 0001104659-17-038155 · a4.xml · nonDerivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 11:57 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | GrantRestricted Stock Units · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-037649 · a4.xml · derivative · entry 1 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on June 2, 2018. F2 · derivative.expiration_date: The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on June 2, 2018. Read SEC document |
| June 02, 2017 Filed Jun 5, 2018 16:42 UTC | T2 Biosystems, Inc. TTOO · Entity 11728 | Exercise / conversionRestricted Stock Units · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-015110 · doc4.xml · derivative · entry 3 Lapidus Stanley · CIK 0001678195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 2, 2017 the reporting person was granted 18,000 RSUs that vested on June 2, 2018. F3 · derivative.expiration_date: On June 2, 2017 the reporting person was granted 18,000 RSUs that vested on June 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.